By Fineline Cube Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today plans to sign a “Distribution, Marketing Services and Agency Agreement” with Vietnamese company MKT, granting MKT exclusive marketing and distribution rights for its adalimumab biosimilar within the territory of Vietnam.
Partnership Structure
| Component | Detail |
|---|---|
| Originator Company | Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) |
| Distribution Partner | MKT (Vietnam) |
| Territory | Vietnam (exclusive rights) |
| Product | Adalimumab biosimilar (referencing AbbVie’s Humira) |
| Agreement Type | Distribution, Marketing Services and Agency Agreement |
| Regulatory Status | Marketing application submitted and accepted for review in China |
Product Profile
Adalimumab Biosimilar Characteristics
- Reference Product: AbbVie’s Humira (adalimumab)
- Development Category: Category 3.3 for therapeutic biological products (China classification)
- Indications: Rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn’s disease
- Biosimilar Status: Developed through comprehensive comparability studies to reference product
Strategic Rationale
- Market Entry Strategy: Leverages local partner expertise for efficient Vietnam market penetration
- Biosimilar Opportunity: Addresses growing demand for affordable biologic alternatives in Southeast Asia
- Regulatory Alignment: Builds on Chinese regulatory progress to support international expansion
- Commercial Infrastructure: Utilizes MKT’s established distribution network and market knowledge
Market Context
- Vietnam Biologics Market: Rapidly growing segment with increasing government support for biosimilars
- Adalimumab Market Size: Global adalimumab market valued at USD 18.4 billion in 2025 despite biosimilar competition
- Southeast Asia Opportunity: Limited biosimilar availability creates significant pricing and access advantages
- Regulatory Pathway: Vietnam’s biosimilar approval framework increasingly aligned with international standards
Competitive Landscape
- Global Biosimilar Competition: Multiple adalimumab biosimilars approved in major markets including EU, US, and China
- Local Manufacturing Advantage: Potential for cost-effective production supporting competitive pricing
- First-Mover Potential: Early entry into Vietnam’s adalimumab biosimilar market
- Portfolio Diversification: Expands Buchang’s international presence beyond traditional Chinese medicine products
Forward-Looking Statements
This brief contains forward-looking statements regarding strategic partnerships, regulatory approvals, market opportunities, and commercial expectations. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market adoption challenges, and execution risks in international business development.-Fineline Info & Tech